eFoodSafety Launches Cinnechol TM , An All-Natural Alternative To Conventional Cholesterol Drugs
eFoodSafety.com (OTCBB: EFSF, http://www.efoodsafety.com), a researcher, developer, and marketer of whole food nutraceutical products, has launched an all-natural supplement, called Cinnechol™ (http://www.cinnechol.com), that offers a complementary and/or alternative solution to traditional cholesterol drugs.
Cholesterol, Blood Pressure Control May Reverse Atherosclerosis In Adults With Diabetes
Aggressively lowering cholesterol and blood pressure levels below current targets in adults with type 2 diabetes may help to prevent - and possibly reverse - hardening of the arteries, according to new research supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.
Merck Receives Not Approvable Letter From FDA For MK-0524A ER Niacin laropiprant
Merck & Co., Inc. received a Not Approvable action letter from the U.S. Food and Drug Administration (FDA) for the Company's New Drug Application (NDA) for MK-0524A (ER niacin/laropiprant) for the treatment of primary hypercholesterolemia or mixed dyslipidemia.
Effects Of Rimonabant On Cardiometabolic Risk Profile Include Loss Of Visceral Fat And Mobilization Of Liver Fat
At a late breaking presentation made on April 29th during the Annual meeting of the European Atherosclerosis Society held in Istanbul, the investigators of ADAGIO-LIPIDS presented the key findings of a one year trial aiming at further studying the effects of rimonabant on several features of HDL and on a comprehensive set of cardiometabolic markers.
High Cholesterol In Your 40s Increases Risk Of Alzheimer's Disease
People with high cholesterol in their early 40s are more likely to develop Alzheimer's disease than those with low cholesterol, according to research that will be presented at the upcoming American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12-19, 2008.
LifeCycle Pharma Announces Positive Data From LCP-AtorFen Phase II Clinical Program
LifeCycle Pharma A/S (OMX:LCP) announced positive results from the company's Phase II clinical program with LCP-AtorFen, a fixed-dose combination product of atorvastatin and fenofibrate for the treatment of mixed dyslipidemia. LCP-AtorFen is a convenient single tablet with a once-daily dosage profile and is without food effect.
Genes That Protect Against Atherosclerosis Identified
One way of combating atherosclerosis is to reduce levels of "bad cholesterol" in the blood. Scientists at the Swedish medical university Karolinska Institutet have now identified the genes that bring about this beneficial effect.
Lloydspharmacy Study Shows The Average UK Heart Is Five Years Older Than Its Owner
Based on an analysis of heart health checks conducted at branches of Lloydspharmacy, and using a protocol developed by Unilever and Boston University, the study shows that people's hearts are aging faster than they should. The research is based on a sample of more than 3000 tests conducted on adults less than 60 years old.
Cholesterol-Associated Gene Variants Can Predict Cardiovascular Events
A study appearing in this week's New England Journal of Medicine confirms that a combination of gene variants previously associated with cholesterol levels does reflect patients' cholesterol levels and can signify increased risk of heart attack, stroke or sudden cardiac death.
VAP Test Helps Researchers Uncover Best Cholesterol Lowering Treatment For Type II Diabetes
The VAP cholesterol test from Atherotech is helping physicians pinpoint the most effective cholesterol and heart disease risk lowering treatments in Type II diabetes patients, providing valuable and potentially lifesaving information to diabetics and the doctors who treat them.